A Study of LY4064912 in Healthy Participants and With Overweight or Obesity

Study acronym: YHAA
StatusTerminated
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Trial terminated Sponsor's reason: Sponsor Decision
    • Final enrollment: 77 participants (planned 144)
    • Primary completion date changed from estimate of Nov 2026 to Aug 26, 2026
    v9
  2. Enrollment closed, study ongoing
    • Site details revised at 3 of 3 sites
    v8
  3. Site details revised at 1 of 3 sitesv7
  4. Primary and study completion dates: Oct 2026 to Nov 2026
    • Site contacts updated at 2 of 3 sites
    v6
  5. Site contacts updated at 1 of 3 sitesv5
Show 3 earlier versionsHide 3 earlier versions
  1. Site details revised at 1 of 3 sitesv4
  2. Site contacts updated at 1 of 3 sitesv3
  3. Site contacts updated at 1 of 3 sitesv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
365 trials monitored
See 16 trials at risk
Obesity
3,898 trials monitored
See 160 trials at risk
The purpose of this study is to evaluate how well LY4064912 is tolerated and what side effects may occur in healthy participants and participants with overweight and obesity - global. The study drug will be administered either subcutaneously (SC) (under the skin) or infusion intravenously (IV) (into a vein in the arm). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
Trial Details
NCT Number NCT07152002
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Overweight or Obesity, Healthy
Related terms Obesity, Overweight
Enrollment 77 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov